Generated by AI
Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that develops medicine, diagnostics, and biodefense products. The company integrates artificial intelligence, genomics, and living biological systems to decode disease mechanisms and identify therapeutic targets. Its pipeline includes genetically modified dendritic cell therapeutic vaccines, such as RENB-DC11 for pancreatic cancer and RENB-DC20 for breast cancer treatment. Lunai Bioworks operates through multiple segments, including RENB, BioSymetrics, and RENC. The company employs proprietary AI platforms combined with zebrafish models to uncover drug efficacy, safety profiles, and clinical biomarkers that traditional research methods may overlook. By integrating phenotypic, proteomic, and genomic data, Lunai Bioworks aims to create clear pathways from disease discovery to patient benefit, focusing on precision medicine approaches for oncology and other therapeutic areas. Headquartered in Los Angeles, California, the company serves both the United States and Netherlands markets.
Website2080 Century Park East
Los Angeles, CA, 90067
United States
The latest articles about RENB.
Tipranks Press Release.
Detailed price information for Lunai Bioworks Inc (LNAI-Q) from The Globe and Mail including charting and trades.
--Lunai Bioworks, Inc., a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing Parkinson's disease discovery and validation platform. The collaboration is designed to connect patient subtypes identified by...
Summary of Sep 25's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about RENB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.